(Q35090042)

6 August 2017

title

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions (English)

1 reference

6 August 2017

0 references

Timothy Kinney

1

1 reference

6 August 2017

Matthew Rawlins

2

1 reference

6 August 2017

Richard Kozarek

3

1 reference

6 August 2017

Renée France

4

1 reference

6 August 2017

David Patterson

5

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

The American Journal of Gastroenterology

6 August 2017

published in

1 reference

6 August 2017

volume

98

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

608-612

1 reference

Update in medical treatment of Crohn's disease

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Anti-TNF therapy and malignancy - a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Mortality associated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Infliximab in Crohn's disease: first anniversary clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Mechanisms in failure of infliximab for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07286.X

10.1111/J.1572-0241.2003.07286.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference